SCHEMBL2093791

SCHEMBL2093791

[CH2]OC/C=C/c1cccc(C(F)(F)F)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFE2L2 Q16236 1/20 0.53
FBP1 P09467 1/20 0.50
P4HB P07237 1/20 0.44
MEN1 O00255 1/20 0.44
LMNA P02545 1/20 0.44
HSP90AA1 P07900 1/20 0.44
MAPT P10636 1/20 0.44
PKM P14618 1/20 0.44
KMT2A Q03164 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
CHRNB2 P17787 1/20 0.44
CHRNB4 P30926 1/20 0.44
CHRNA3 P32297 1/20 0.44
CHRNA7 P36544 1/20 0.44
CHRNA4 P43681 1/20 0.44
MAOB P27338 6/20 0.44
IDO1 P14902 2/20 0.44
MAOA P21397 2/20 0.41
HTT P42858 1/20 0.41
THRB P10828 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2093792 1.00 NFE2L2 (0.53) NFE2L2FBP1P4HBMEN1LMNA
SCHEMBL2093427 0.83 PIM1 (0.42) NFE2L2MAOBIDO1MAOA
SCHEMBL2093429 0.83 PIM1 (0.42) NFE2L2MAOBIDO1MAOA
SCHEMBL2092212 0.82 PPARG (0.41) NFE2L2FBP1IDO1
SCHEMBL5543896 0.81 FBP1 (0.49) NFE2L2FBP1P4HBMEN1LMNA
SCHEMBL5543899 0.81 FBP1 (0.49) NFE2L2FBP1P4HBMEN1LMNA
SCHEMBL1048410 0.80 NFE2L2 (0.53) NFE2L2FBP1P4HBMEN1LMNA
SCHEMBL1048412 0.80 NFE2L2 (0.53) NFE2L2FBP1P4HBMEN1LMNA
SCHEMBL2095430 0.79 FBP1 (0.57) NFE2L2FBP1P4HBMEN1LMNA
SCHEMBL80957 0.79 NFE2L2 (0.56) NFE2L2FBP1P4HBMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 NFE2L2 418/4885FBP1 784/4885P4HB 3343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.